In the May 29 issue of New Delhi's Business Standard, Harinder Sikka analyzes the "pharma impasse" that makes U.S. medicines unaffordable in India. While the problem is mostly due to drug patents, corporate pricing policies, and Indian poverty, Sikka's preferred solution, differential pricing, requires open access: "To make this approach feasible, it is mandatory to share global knowledge, establish partnership between public and private and open access to scientific database."
Posted by
Peter Suber at 5/28/2003 03:56:00 PM.
The open access movement:
Putting peer-reviewed scientific and scholarly literature
on the internet. Making it available free of charge and
free of most copyright and licensing restrictions.
Removing the barriers to serious research.
